Skip to main content

Breadcrumb

  1. Home

Liquid biopsies for residual disease and recurrence

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid biopsies for residual disease and recurrence

Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study

Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system

Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • …
  • Next page Next
  • Last page Last
Subscribe to